Premium
Combination Treatment with Cisplatin and Schizophyllan for 7,12‐dimethylbenz(a)anthracene‐Induced Rat Ovarian Adenocarcinoma
Author(s) -
Sugiyama Toru,
Nishida Takashi,
Kumagai Seisuke,
Imaishi Kiyohisa,
Ushijima Kimio,
Kataoka Akio,
Yakushiji Michiaki
Publication year - 1995
Publication title -
journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1340-9654
DOI - 10.1111/j.1447-0756.1995.tb01047.x
Subject(s) - cisplatin , dmba , immunohistochemistry , adenocarcinoma , medicine , chemotherapy , cytotoxic t cell , cancer research , ctl* , oncology , chemistry , immunology , antigen , cancer , in vitro , carcinogenesis , biochemistry , cd8
Objective : Experimental chemotherapy was conducted to investigate the combined effect of Schizophyllan (SPG) and Cisplatin (CDDP). Methods : Rats with 7,12‐dimethylbenz(a)anthracene (DMBA)‐induced ovarian adenocarcinoma received SPG and/or CDDP, were observed for the anti‐tumor effect of the drugs and were subjected to immunohistochemical study. Results : 1 Tumor reduction was enhanced by the combined use of SPG and CDDP; 2 The survival rate of rats given SPG alone was significantly higher than that of the control rats, and treatment with SPG combined with CDDP tended to improve the survival rate; 3 Immunohistochemically, an infiltrative increase in cytotoxic T‐lymphocytes (CTL) was induced, although the development of helper T‐cells and macrophages was immunohistochemically weak at the tumor site. Conclusion : The administration of SPG enhanced the anti‐tumor effect of CDDP.